Janux Therapeutics (JANX) Share-based Compensation (2020 - 2026)
Janux Therapeutics (JANX) reported Share-based Compensation of $9.3 million for Q1 2026, down 13.39% year-over-year from $10.7 million in Q1 2025, and down 2.59% on a QoQ basis from $9.5 million in Q4 2025.
Janux Therapeutics (JANX) has 7 years of Share-based Compensation data on file, last reported at $9.3 million in Q1 2026.
- Quarterly Share-based Compensation fell 13.39% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.8 million (up 1.81% YoY) and the FY2025 annual result came in at $40.2 million, up 21.81% from the prior year.
- Share-based Compensation slipped to $9.3 million in Q1 2026 per JANX's latest filing, from $9.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $15.4 million in Q3 2024 and bottomed at $4.0 million in Q1 2022.
- The 5-year median for Share-based Compensation is $5.6 million (2024), against an average of $7.0 million.
- The widest annual swing landed in 2022, when Share-based Compensation surged 3117.89%; it then sank 41.22% in 2025.
- Tracing JANX's Share-based Compensation over 5 years: stood at $4.2 million in 2022, then climbed by 6.61% to $4.5 million in 2023, then jumped by 39.44% to $6.3 million in 2024, then soared by 52.22% to $9.5 million in 2025, then retreated by 2.59% to $9.3 million in 2026.
- Per Business Quant, the three latest JANX Share-based Compensation figures stand at $9.3 million (Q1 2026), $9.5 million (Q4 2025), and $9.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Janux Therapeutics | 914.29 Mn | 914.29 Mn | - | 9.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.27 Mn |
| Mar 31, 2026 | 9.27 Mn |
| Dec 31, 2025 | 9.52 Mn |
| Dec 31, 2025 | 9.52 Mn |
| Sep 30, 2025 | 9.04 Mn |
| Sep 30, 2025 | 9.04 Mn |
| Jun 30, 2025 | 10.96 Mn |
| Jun 30, 2025 | 10.96 Mn |
| Mar 31, 2025 | 10.70 Mn |
| Mar 31, 2025 | 10.70 Mn |
| Dec 31, 2024 | 6.25 Mn |
| Dec 31, 2024 | 6.25 Mn |
| Sep 30, 2024 | 15.39 Mn |
| Sep 30, 2024 | 15.39 Mn |
| Jun 30, 2024 | 5.76 Mn |
| Jun 30, 2024 | 5.76 Mn |
| Mar 31, 2024 | 5.63 Mn |
| Mar 31, 2024 | 5.63 Mn |
| Dec 31, 2023 | 4.48 Mn |
| Dec 31, 2023 | 4.48 Mn |
| Sep 30, 2023 | 4.55 Mn |
| Sep 30, 2023 | 4.55 Mn |
| Jun 30, 2023 | 5.50 Mn |
| Jun 30, 2023 | 5.50 Mn |
| Mar 31, 2023 | 5.47 Mn |
| Mar 31, 2023 | 5.47 Mn |
| Dec 31, 2022 | 4.21 Mn |
| Dec 31, 2022 | 4.21 Mn |
| Sep 30, 2022 | 4.60 Mn |
| Sep 30, 2022 | 4.60 Mn |
| Jun 30, 2022 | 4.44 Mn |
| Jun 30, 2022 | 4.44 Mn |
| Mar 31, 2022 | 3.96 Mn |
| Mar 31, 2022 | 3.96 Mn |
| Dec 31, 2021 | 2.94 Mn |
| Dec 31, 2021 | 2.94 Mn |
| Sep 30, 2021 | 2.57 Mn |
| Sep 30, 2021 | 2.57 Mn |
| Jun 30, 2021 | 1.28 Mn |
| Jun 30, 2021 | 1.28 Mn |
| Mar 31, 2021 | 123,000.00 |
| Mar 31, 2021 | 123,000.00 |
| Dec 31, 2020 | 40,000.00 |
| Dec 31, 2020 | 40,000.00 |
| Sep 30, 2020 | 28,000.00 |
| Sep 30, 2020 | 28,000.00 |
| Jun 30, 2020 | 2,000.00 |
| Jun 30, 2020 | 2,000.00 |